Trial
NCT03670069
Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Fred Hutchinson Cancer Center
Collaborators
Incyte Corporation
Condition
Metastatic Leiomyosarcoma
Intervention
Itacitinib
Why stopped
The study was terminated early with 27 out of 28 planned subjects enrolled. This decision was multifactorial, including slow enrollment in the last remaining cohort and a lack of evidence of clinical benefit.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-05-08